Small Molecule · NTX-1955

NTX-1955

Oral, first-in-class positive allosteric modulator (PAM) selective for GABA-A receptors containing the gamma1 subunit, discovered by Roche as RO7308480 and in-licensed by Newleos Therapeutics for generalized anxiety disorder. Benzodiazepines act on gamma2-containing GABA-A receptors found throughout the brain, which drives sedation, ataxia and cognitive impairment; gamma1 subunits are instead enriched in the amygdala and connected anxiety circuitry, so a gamma1-selective PAM is designed to deliver benzodiazepine-like anxiolysis without those effects. In vitro it binds gamma1 about 100-fold more tightly than gamma2 (Ki 20 nM vs 2000 nM). In healthy volunteers (ECNP 2026) 5-15 mg produced no substantial NeuroCart impairment versus placebo, 25 mg affected only adaptive tracking, PET showed 5-45% gamma1 occupancy with no detectable gamma2 occupancy, and the effective half-life was about 24 hours. Three Newleos Phase 1b studies (two in the Netherlands, one in UK patients with GAD) ran in 2025-2026 to inform a Phase 2 efficacy study.

Also known as: NTX-1955, NTX 1955, NTX1955, RO7308480, RO-7308480

Key facts

Modality
Small molecule
Highest phase
Phase 1
Trials
4 tracked

Mechanism of action#

Positive allosteric modulator of GABA-A receptors that contain the gamma1 subunit (GABRG1). Classical benzodiazepines bind the alpha/gamma2 interface of gamma2-containing receptors, which are ubiquitous and mediate sedation, ataxia and cognitive impairment; gamma1-containing receptors are enriched in the amygdala and connected nuclei that process fear and anxiety. In radioligand binding NTX-1955 showed Ki 20 nM at gamma1 versus 2000 nM at gamma2 (100-fold selectivity), the inverse of alprazolam (gamma1 4000 nM, gamma2 20 nM). In humans, PET with the gamma1-selective tracer [11C]-RO7285378 showed dose-related gamma1 occupancy of 5-45%, while [11C]-flumazenil binding (gamma2) was not reduced. Newleos reports dose-dependent anxiolytic activity in preclinical anxiety models matching benzodiazepines without their side-effect profile.

10 nM100 nM1 µM10 µMGABA-A receptor gamma-1GABA-A receptor gamma-1 — PAM — Ki 20 nMKi 20 nMGABA-A receptor gamma-2GABA-A receptor gamma-2 — PAM — Ki 2 µMKi 2 µM
Binding affinity on a log scale — further left is more potent. Values from the sourced literature (see table).
TargetActionAffinity
GABA-A receptor gamma-1primaryGABRG1PAMKi 20 nMⓘ
GABA-A receptor gamma-2GABRG2PAMKi 2000 nMⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
NTX-1955 oral capsule (once daily)
Oral capsule. Roche SAD/food-effect study BP43318 used single ascending oral capsule doses (six escalation steps). Healthy-volunteer NeuroCart study: 5, 10, 15 and 25 mg dosed for 7 days (Days 1 and 7 assessed). UK GAD study NTX-1955-103: 15 mg or 25 mg once daily for 14 days.
OralOnce dailyt½ 24 h

Development timeline#

2023202420252026TodayPhase 122 Oct 2026 — Trial (portion) completed — NTX-1955-102 CO2-challenge study ends10 Oct 2026 — readout (met) — Healthy-volunteer NeuroCart and PET data (ECNP 2026): NTX-1955 5-15 mg caused no substantial CNS impairment vs placebo, 25 mg affected only adaptive tracking, with 5-45% gamma1 receptor occupancy and no detectable gamma2 occupancy, versus broad impairment with alprazolam.3 Jun 2026 — Trial (portion) completed — UK NTX-1955 study in GAD patients (NTX-1955-103) ends with 32 enrolled1 Apr 2026 — Trial started — First GAD patient dosed in UK Phase 1b study of NTX-1955 (NTX-1955-103)22 Dec 2025 — Trial (portion) completed — NTX-1955-101 healthy-volunteer brain-effects study ends10 Sept 2025 — Conference presentation — Roche/Newleos present preclinical gamma1-selective GABAA PAM data at WCBP 202521 Aug 2025 — Trial started — Second Phase 1b study of NTX-1955 (CO2 challenge, NTX-1955-102) starts in the Netherlands2 Jul 2025 — phase change — First Newleos study under its sponsorship: NTX-1955-101 authorised in the EU on 2025-06-24 and recruitment started in the Netherlands on 2025-07-02 (per the CTIS register). Newleos announced on 2025-07-23 that CTAs had been filed for two EU Phase 1b studies and dosing had commenced in one.2 Jul 2025 — Trial started — First Newleos Phase 1b study of NTX-1955 (NTX-1955-101) starts in the Netherlands13 Feb 2025 — Licensing deal — Newleos in-licenses NTX-1955 (RO7308480) and three other neuropsychiatry assets from Roche15 Feb 2022 — phase change — Roche first-in-human single-ascending-dose and food-effect study of RO7308480 (protocol BP43318, EudraCT 2021-004128-13) in healthy participants; ISRCTN lists recruitment 2022-02-15 to 2022-06-20 and overall end 2022-07-19. Earliest dated clinical activity found for the compound.
Phase change Readout Event UpcomingHover a marker for details.
Phase 1Feb 2022 – Oct 2026
  1. Trial (portion) completedNTX-1955-102 CO2-challenge study ends↗
  2. metHealthy-volunteer NeuroCart and PET data (ECNP 2026): NTX-1955 5-15 mg caused no substantial CNS impairment vs placebo, 25 mg affected only adaptive tracking, with 5-45% gamma1 receptor occupancy and no detectable gamma2 occupancy, versus broad impairment with alprazolam.↗
  3. Trial (portion) completedUK NTX-1955 study in GAD patients (NTX-1955-103) ends with 32 enrolled↗
  4. Trial startedFirst GAD patient dosed in UK Phase 1b study of NTX-1955 (NTX-1955-103)↗
  5. Trial (portion) completedNTX-1955-101 healthy-volunteer brain-effects study ends↗
  6. Conference presentationRoche/Newleos present preclinical gamma1-selective GABAA PAM data at WCBP 2025↗
  7. Trial startedSecond Phase 1b study of NTX-1955 (CO2 challenge, NTX-1955-102) starts in the Netherlands↗
  8. First Newleos study under its sponsorship: NTX-1955-101 authorised in the EU on 2025-06-24 and recruitment started in the Netherlands on 2025-07-02 (per the CTIS register). Newleos announced on 2025-07-23 that CTAs had been filed for two EU Phase 1b studies and dosing had commenced in one.↗
  9. Trial startedFirst Newleos Phase 1b study of NTX-1955 (NTX-1955-101) starts in the Netherlands↗
  10. Licensing dealNewleos in-licenses NTX-1955 (RO7308480) and three other neuropsychiatry assets from Roche↗
  11. Roche first-in-human single-ascending-dose and food-effect study of RO7308480 (protocol BP43318, EudraCT 2021-004128-13) in healthy participants; ISRCTN lists recruitment 2022-02-15 to 2022-06-20 and overall end 2022-07-19. Earliest dated clinical activity found for the compound.↗

NTX-1955 for Generalized anxiety disorder#

Phase 1ActiveGeneralized anxiety disorder indication →

NTX-1955 (RO7308480), an oral GABA-A gamma1-selective positive allosteric modulator, for generalized anxiety disorder (GAD). Roche completed the Phase 1 package (single and multiple ascending dose, drug-drug interaction and receptor occupancy studies; the SAD/food-effect study BP43318 ran in 2022) before licensing the compound to Newleos Therapeutics, which announced the deal in February 2025. Newleos then ran three studies it calls Phase 1b (registered as Phase I): NTX-1955-101, a brain-effects study in 18 healthy adults in the Netherlands (June-December 2025); NTX-1955-102, a CO2-challenge anxiety model study in 60 healthy participants in the Netherlands (August 2025-October 2026); and NTX-1955-103 (ISRCTN18346744), a UK randomized, double-blind, placebo-controlled study of 15 mg or 25 mg once daily versus placebo for 2 weeks in adults aged 18-55 with GAD (primary endpoint safety and tolerability; 32 enrolled; ended June 2026). Healthy-volunteer data presented at ECNP 2026 showed gamma1 target engagement without benzodiazepine-like impairment at 5-15 mg. Newleos says the Phase 1b data will guide dose selection and the design of a Phase 2 efficacy study; no Phase 2 is registered and no GAD patient results have been announced.

Readouts

  • 2026-10-10ReportedFull resultsmet

    Healthy-volunteer NeuroCart and PET data (ECNP 2026): NTX-1955 5-15 mg caused no substantial CNS impairment vs placebo, 25 mg affected only adaptive tracking, with 5-45% gamma1 receptor occupancy and no detectable gamma2 occupancy, versus broad impairment with alprazolam. ↗

Clinical trials#

NTX-1955-103Phase 1Completedn=32

A multicentre, double-blind, randomised, placebo-controlled trial to evaluate safety and tolerability of NTX-1955 in adult patients with generalised anxiety disorder (ISRCTN18346744)

Started Feb 2026· Primary completion Jun 2026

NTX-1955-102Phase 1Completedn=60

CO2 challenge study of NTX-1955 in healthy participants (EU CT 2025-522281-68-00)

Started Aug 2025· Primary completion Oct 2026

NTX-1955-101Phase 1Completedn=18

A study to examine the effects of oral NTX-1955 on the brain in healthy adults (EU CT 2025-521829-32-00)

Started Jul 2025· Primary completion Dec 2025

BP43318Phase 1Completedn=96

A Phase I randomized, investigator/participant-blind, adaptive, single ascending dose, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and food effects of RO7308480 following oral administration in healthy participants

Started Feb 2022· Primary completion Jul 2022

Conference coverage#

NTX-1955 appears in 1 CNS Pulse conference abstract:

Sources#

  1. ECNP 2026 abstract PS01-1026 (Hopkins et al.) - NTX-1955 gamma1-selective PAM in human volunteers — CNS Pulse (reproducing the ECNP 2026 online programme)
  2. EU CT 2025-521829-32-00 (NTX-1955-101) - A study to examine the effects of oral NTX-1955 on the brain in healthy adults — CTIS.eu (mirror of the EU Clinical Trials Information System register)
  3. EU CT 2025-522281-68-00 (NTX-1955-102) - CO2 challenge study of NTX-1955 in healthy participants — CTIS.eu (mirror of the EU Clinical Trials Information System register)
  4. Hopkins SC, et al. Targeting gamma1-containing GABA-A receptors spares gamma2-benzodiazepine mediated neurophysiological impairments in human volunteers - poster PS01-1026, 39th ECNP Congress, Munich, 2026 — Newleos Therapeutics, Inc.
  5. ISRCTN18346744 (NTX-1955-103) - A study to evaluate the safety of NTX-1955 in patients with generalised anxiety disorder — ISRCTN registry
  6. ISRCTN18346744 full record (XML API) - arms, doses, dates, final enrolment — ISRCTN registry
  7. ISRCTN63295298 (BP43318, EudraCT 2021-004128-13) - first-in-human SAD and food-effect study of RO7308480 in healthy participants — ISRCTN registry
  8. ISRCTN63295298 full record (XML API) - Roche RO7308480 SAD/food-effect study dates and enrolment — ISRCTN registry
  9. Newleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized Anxiety Disorder (2026-04-01) — Newleos Therapeutics, Inc. (via BioSpace)
  10. Newleos Therapeutics Announces Poster Presentation to be Featured at the 2025 World Congress of Biological Psychiatry (2025-09-09) — Newleos Therapeutics, Inc.
Show all 11 sources
  1. Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing (2025-02-13) - names NTX-1955 (RO7308480) — Newleos Therapeutics, Inc.